Lumera (LMRA) surged 15% early Tuesday after the nanotech player said Harvard Medical School researchers are using its ProteomicProcessor Biosensor.
The Bothell, Wash., company said it has placed four beta units with research organizations to demonstrate and establish new applications. The Harvard collaboration is focused on integrating Nucleic Acid Programmable Protein Array technology with the ProteomicProcessor to read and analyze the biochip.
Lumera shares have been red hot this month. Just two weeks ago, shares tripled in a single day on the claim that Lumera had "completed successful testing of its millimeter wave wireless bridge that will enable government and commercial entities to transmit vast amounts of data via a variety of high speed telecommunications networks."
Shares rose $1.03 Tuesday to $7.38.